What would it look like if your specialty pharmacy spend dropped 30–70%?
That’s the question we put to every client — before we tell them anything else.
More than half the clients we engage don’t actually know their total pharmacy spend. Of the ones who do, almost none can tell you which drugs are driving it — or whether there’s a real alternative for any of them.
The right consultant doesn’t guess. They dig into your claims data, find out exactly which levers actually move your spend, and build a program around what your group specifically needs — not a generic pitch.
We’ve seen drug spend cut 30–70% doing this. That’s not a rounding error. That’s real money staying in the employer’s pocket, and a renewal that rewards you for making the change.
For most of the last two decades, nobody wanted to talk about it. That silence is exactly why the money’s still on the table. We pull back the curtain — on the drugs, the contracts, and the rebates — because that’s where the permanent savings live.
High-cost drugs get reused year after year. Members stay on them for multi-year runs. Left alone, that’s a locked-in trajectory of double-digit renewal increases — not a bad year, a pattern. Without the right strategy — or the right person reading the data — you don’t climb out of it. You just keep paying for it.
A free review shows you exactly where you stand — in plain English, no obligation.